Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

men. The primary endpoint of the study is PFS. This global study, conducted by Janssen outside the US, is recruiting and Janssen plans to enroll 280 patients.
  • SHINE (MCL3002): Phase III study of ibrutinib in combination with bendamustine and rituximab in elderly patients with newly diagnosed MCL. This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in patients 65 years or older with newly diagnosed MCL. The primary endpoint of the study is PFS. This global study, conducted by Janssen, is recruiting and Janssen plans to enroll 520 patients.
  • MCL4001: A multicenter, open label Expanded Access Program (EAP) for ibrutinib as a monotherapy in relapsed/refractory (R/R) MCL patients has been initiated in the US by Janssen. EAPs are clinical studies allowed under certain circumstances by the FDA. They are designed to provide a mechanism for access to an investigational drug to treat patients with a serious or immediately life-threatening diseases or conditions until the time of an anticipated U.S. marketing approval. Further information about this program can be found on www.clinicaltrials.gov.
  • DLBCL

  • PCYC-1106: Phase II study of ibrutinib in patients with relapsed or refractory DLBCL. This trial is a multicenter, open-label study designed to assess the activity of ibrutinib in two genetically distinct subtypes of DLBCL, the activated B-cell (ABC) subtype and the germinal center B-cell (GCB) subtype. This trial is active in several US sites and Pharmacyclics has enrolled 70 patients with updated results most recently published at EHA in June 2013. In July a new cohort with ibrutinib dosed at 840mg in patients with non-GCB subtype DLBCL was initiated. This cohort will increase the enrollment target for this study to 125 patients.
  • DBL1002: Phase Ib dose escalating stu
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
    (Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
    (Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
    Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
    (Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
    (Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
    (Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
    (Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern ... suffering from depression . , A team ... mechanism by which ghrelin (a hormone with natural anti-depressant ... a potentially powerful new treatment for depression in the ... , The study, published online in April,s issue ...
    (Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
    Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
    ... pill that will help protect and even treat hearing loss from ... say it has picked up steam in just the past few ... Marines will face rifle training with not only foam plugs in ... herbal tea. ,They'll take it with every meal during their ...
    ... observational studies previously conducted in elderly populations have ... performed before intracoronary stents and use of glycoprotein ... Hanoch Hod, of Chaim Sheba Medical //Center in ... patients aged 70 or older treated for ST-elevation ...
    ... new studies have identified genetic activity that appears to ... alters a person's perceptions of reality, emotions and thought ... of the world's population, typically surface during the late ... Rockefeller, University in New York and colleagues identified two ...
    ... vasectomy, contraception is typically left up to the woman. ... in a woman's contraceptive repertoire. Until now, men have ... searching for new options. Now, they may have one.// ... 12 percent. Vasectomies are considered permanent. Dr. Wang, of ...
    ... periods ,Seasonale, a new drug approved by the Food ... women's periods to four a year by taking the hormones ... spans of time.// ,Seasonale would be another alternative ... prevention of pregnancy and are comfortable taking a hormonal contraceptive, ...
    ... for some doctors who think it's time to replace the ... invented it in the early 1800s. "The stethoscope is based ... to distinguish between a heart that is beating well, and ... heart muscle is very weakened, but unless that weakening leads ...
    Cached Medicine News:Health News:Pill might be able to reduce the damage loud noise does to your hearing 2Health News:Pill might be able to reduce the damage loud noise does to your hearing 3Health News:Angioplasty plus stenting better than thrombolysis for elderly patients with AMI, 2Health News:Gene Activity connected to Schizophrenia 2Health News:New birth control to limit women's periods 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: